Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Oligodendroglioma 1Myelodysplastic Syndromes 1Lung Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Head and Neck Neoplasms 1Glioblastoma 1Cytopenia 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cisplatin 252Radiotherapy 176Cetuximab 144pembrolizumab 120Docetaxel 96Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Gefitinib 21Cyclophosphamide 21Surveys and Questionnaires 20Surgical Procedures, Operative 19Standard of Care 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15Low-Level Light Therapy 14Everolimus 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × DNA × Clear all
NCT02211027 2017-09-07

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

University of Pittsburgh

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡